A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This study is a phase I, randomized, double-blind, placebo-controlled, single-center, to evaluate the safety, tolerability, and pharmacokinetics (PK) of GLPG3667 after an oral single dose (SD) of GLPG3667 (part 1) and after oral multiple doses (MD) for 13 days of GLPG3667 (part 2) in healthy male subjects.
Epistemonikos ID: bd9d3b59b27d6146f3bd5b2d3106ffde9f02f089
First added on: May 09, 2024